Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORF-057 in Healthy Subjects
NCT04580745Phase 1Completed
- Sponsor
- Morphic Therapeutic
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) and Crohn's disease comparing MORF-057 with Placebo (2 arms). Primary endpoints: Incidence of adverse events and safety signals observed during single and multiple ascending doses of MORF-057, Maximum Plasma Concentration (Cmax) of MORF-057 in a fed state and 1 more. Started Sep 2020; status: completed.
02
Drugs
LY4268989
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04580745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580745.